From: Prevalence of chronic kidney disease in patients with type 2 diabetes in Spain: PERCEDIME2 study
eGFR, | Normoalbuminuria | Microalbuminuria | Macroalbuminuria |
---|---|---|---|
mL/min per 1.73 m2 | ACR < 30 mg/g | ACR 30–300 mg/g | ACR > 300 mg/g |
≥ 90 (Stage 1) | 298 (26%) | 36 (3.14%) | 4 (0.35%) |
60-89.9 (Stage 2) | 528 (46.1%) | 68 (6%) | 5 (0.45%) |
45-59.9 (Stage 3A) | 99 (8.65%) | 26 (2.3%) | 8 (0.7%) |
30–44.9 (Stage 3B) | 40 (3.5%) | 15 (1.3%) | 5 (0.45%) |
< 30 (Stages 4–5) | 4 (0.35%) | 4 (0.35%) | 5 (0.45%) |
UACR | Normoalbuminuria | Microalbuminuria | Macroalbuminuria |
N (%) | 969 (84.6%) | 149 (13.0%) | 27 (2.4%) |
eGFR ≥ 60 |  |  |  |
mL/min per 1.73Â m2 | 939 (82%) | Â | Â |
eGFR < 60 |  |  |  |
mL/min per 1.73Â m2 | 206 (18%) | Â | Â |
Any type of CKD | 319 (27.9%) | Â | Â |